--New assays for the Panther Fusion and Novodiag Systems further build on Hologic’s leading molecular scalable solutions offering to European customers-- The Panther Fusion SARS-CoV-2/Flu A/B/RSV ...

Hologic, Inc.’s HOLX Aptima SARS-CoV-2 molecular diagnostic test recently got CE marking for its use with saliva sample. This assay, which runs on fully automated Panther system, detects the genetic ...

Hologic has secured a $119M contract to increase production capacity for diagnostic kits and test consumables in support of government efforts to sustain the U.S. industrial base through the ...

Marlborough medical device manufacturer Hologic has received U.S. Food and Drug Administration clearance for a new combined test that can detect influenza A and B, respiratory syncytial virus (RSV) ...

Though Hologic’s HOLX fiscal second-quarter results were dominated by declines in COVID-19-related diagnostics that drove consolidated quarterly revenue decline of 28% in constant currency, ...

Hologic, Inc.’s HOLX diagnostics business is likely to have witnessed an increase in non-COVID Diagnostics business, banking on growing Panther instruments worldwide. The Breast Health arm is expected ...

Narrow-moat Hologic saw robust fiscal second-quarter performance across its business through January and February, driven by surgical products and diagnostics. However, as COVID-19 spread and ...

In the fourth quarter of fiscal 2025, Diagnostics revenues increased 1.5% in constant currency (CC), driven by higher core ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Aptima® SARS-CoV-2 assay, ...